Financhill
Back

Regeneron Pharmaceuticals 10K Form

Sell
40

REGN
Regeneron Pharmaceuticals

Last Price:
$696.47
Seasonality Move:
1.02%

7 Day Trial

ALL ACCESS PASS

$ 7

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $14.2B
Cash Flow: $995.8M
Price / Cash Flow: 22.3
Annual Sales: $267.78
Price / Book: 2.55

Profitability

EPS (TTM): 38.28000
Net Income (TTM): $4.4B
Gross Margin: $12.2B
Return on Equity: 15.78%
Return on Assets: 12.34%

Regeneron Pharmaceuticals Earnings Forecast

Key Regeneron Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 35 years for REGN is 86.13%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.80% of Gross Profit Margin.
  • The Research & Development expenses have been 36.14% of Revenue.
  • The Interest Expense is 1.25% of Operating Income.
  • The Net Earning history of REGN is 31.07% of Total Revenues.
  • Per Share Earnings over the last 35 years have been positive in 19 years.

Regeneron Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Health Care
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 4.73
Quick Ratio: 3.86

Price-to-Earnings

Trailing P/E Ratio: 17.88
Forward P/E Ratio: 14.57

REGN Technical Analysis vs Fundamental Analysis

Sell
40
Regeneron Pharmaceuticals (REGN) is a Sell

Is Regeneron Pharmaceuticals a Buy or a Sell?